261 studies on Insulin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 261 dated studies on Insulin. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
The ability to accurately predict cardiovascular mortality in Type 2 Diabetes Mellitus patients with Coronary Artery Disease is paramount for enhancing patient care and improving long-term outcomes. Positive findings …
MOTS-c is a novel mitochondrial-derived peptide with potential roles in metabolic regulation, including glucose homeostasis. If this Phase 2a study demonstrates significant improvements in insulin sensitivity and a fa…
Understanding the optimal pre-procedural management for patients on GLP-1RAs like semaglutide is critical for patient safety and procedural efficacy during endoscopy. If a one-week discontinuation significantly reduce…
This pilot study is significant because it explores a novel adjunctive therapeutic strategy for Crohn's disease by targeting metabolic health and weight. If successful, it could demonstrate that GIP/GLP-1 receptor ago…
Understanding the precise mechanisms by which Tirzepatide impacts pancreatic alpha and beta cell function and insulin sensitivity is critically important. This mechanistic insight can refine our understanding of optim…
Understanding the extrapancreatic effects of GIP and GLP-1 is crucial for optimizing current and developing future treatments for type 2 diabetes and obesity. This research will provide critical insights into why comb…
The successful integration of tirzepatide with automated insulin delivery could represent a paradigm shift in Type 1 Diabetes management, offering a novel strategy to improve glucose control beyond current capabilitie…
This planned study is significant because it aims to explore a novel therapeutic avenue for a highly complex patient population: individuals with obesity and chronic kidney failure. If Tirzepatide demonstrates a favor…
This Phase 3 trial is highly significant as it directly compares Tirzepatide, a novel dual GIP/GLP-1 receptor agonist, against a standard rapid-acting insulin, insulin lispro (U100), in a challenging patient populatio…
If successful, this trial could represent a significant advancement for patients with Type 2 Diabetes and renal impairment, a group with limited treatment options and high unmet medical need. Retatrutide could offer a…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
This research reveals a novel physiological mechanism where ghrelin acts as a local vasoconstrictor in pancreatic islets during fasting. This action restricts blood flow, thereby limiting the insulin response to hyper…
This research maps a specific neural circuit through which the brain, via ghrelin signaling, directly influences liver function and systemic lipid and glucose levels. For individuals exploring metabolic optimization, …
This study establishes a robust and efficient theoretical model for ultra-fast calculation of electronic excitation spectra in large systems like proteins and other biomacromolecules. The combination of high accuracy …
**GHRP-2 testing may offer a safer, equally informative alternative to ITT** for evaluating adrenal reserve in patients with hypothalamic or pituitary disease, particularly those for whom insulin-induced hypoglycemia …
This research provides compelling evidence that GHRP-2 can directly stimulate ACTH release from the pituitary gland, even when the hypothalamus is impaired. This direct action on the pituitary could make GHRP-2 a valu…
This research highlights the significant potential of GH-Releasing Peptide-2 (GHRP-2) as a safe, rapid, and reliable diagnostic tool for Growth Hormone Deficiency (GHD) in children. Given that the traditional Insulin …
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that **…
The GHRP-2 test emerges as a viable diagnostic tool for secondary adrenal failure, offering diagnostic power comparable to the established CRH stimulation test. For clinicians, this provides another option for assessi…
The findings suggest that the GHRP-2 test can replace the riskier insulin tolerance test for HPA axis assessment, but its application is highly specific. **Clinicians can consider using the GHRP2T in male patients wit…
This research reveals a novel and critical role for the RECK protein in maintaining the stability and proper function of the GH/IGF-1 axis. The observed discordance between receptor protein levels and their mRNA sugge…
This study highlights **MR-409**'s potential as a beta-cell protective agent, even if it doesn't directly resolve **ER stress**. For individuals concerned with **T2D** progression or beta cell health, this suggests a …
This research clarifies the complex relationship between leptin and the melanocortin system in managing diabetes. For researchers and biohackers, it demonstrates that **simply activating MC3/4R with agonists like Mela…
These findings highlight a critical, often overlooked, variable in preclinical research: associative learning and stress from experimental procedures can confound the physiological effects of a compound. For researche…
The widespread availability of falsified peptides like Melanotan II on the black market poses a direct and severe risk to end-users. Consumers have no assurance of what they are injecting, risking exposure to incorrec…
**Systemic GH secretagogue use — including MK-0677 — does not elevate CNS IGF-1 or GH levels**, which has direct implications for researchers and clinicians who hypothesize that peripheral GH/IGF-1 elevation might pro…
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
This comprehensive review highlights ghrelin's multifaceted nature, demonstrating it is far more than just a GH secretagogue. Understanding ghrelin's broad actions opens new avenues for therapeutic development and dru…
This synthesis highlights the GH/IGF-I axis as a critical endocrine regulator in Alzheimer's disease, offering a novel perspective on its pathogenesis. Understanding this intricate relationship could pave the way for …
**Oral MK-677 at 25 mg/day demonstrably attenuates age-related lean mass loss** and restores `IGF-1` to youthful concentrations, establishing proof-of-concept that `GHSR` agonism can counter one measurable dimension o…
This review underscores the critical need for more robust, evidence-based interventions to address somatopause and its associated age-related conditions. The findings highlight that current GH therapy, despite its pop…
This study establishes that MK-0677 is effective at raising IGF-1 levels in the specific, vulnerable population of hemodialysis patients, a group where anabolic support is critically needed to combat protein-energy wa…
These findings highlight a significant challenge for the long-term use of oral GHSs like MK-677 for growth promotion. While the compound can acutely stimulate a robust GH pulse, the body appears to develop a powerful …
This research highlights the potential of Epithalon as a therapeutic agent to combat age-related metabolic decline and improve pancreatic health. Given that impaired glucose tolerance is a precursor to conditions like…
This research highlights the potential of pineal gland peptides as a novel strategy for combating age-related pancreatic decline. The observed geroprotective effect could lead to new therapeutic approaches for conditi…
This review highlights a critical gap in our understanding of optimal T2DM management during pregnancy, particularly concerning newer, highly effective antidiabetic agents. The limited evidence for novel therapies mea…
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
Free, no account — handy when you're working with Insulin.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account